Literature DB >> 551094

Fate of the synthetic immunoadjuvant, muramyl dipeptide (14C-labelled) in the mouse.

M Parant, F Parant, L Chedid, A Yapo, J F Petit, E Lederer.   

Abstract

Synthetic N-acetylmuramyl-L-alanyl-D-isoglutamine (muramyl dipeptide or MDP) represents the smallest unit that can substitute for whole Mycobacteria in Freund's complete adjuvant. In this paper the fate of 14C-labelled (on the muramyl moiety) MDP is reported. Following intravenous or subcutaneous injection into mice, more than 50% of 14C-MDP was recovered in the urine after 30 min and more than 90% after 2 h. The labelled compound was found unchanged in the urine, as shown by detailed analyses. However, MDP was sequestered for a longer time at the site of injection when administered as a water-in-oil emulsion. Considering the relatively rapid elimination observed, it is suggested that the biological effects of MDP and related compounds, when administered in an aqueous medium, may be due to their activity at minute concentrations and/or an immediate action at the cellular level.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 551094     DOI: 10.1016/0192-0561(79)90028-6

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  44 in total

1.  Effect of muramyl peptides on mitochondrial respiration.

Authors:  N El-Jamal; G M Bahr; K S Echtay
Journal:  Clin Exp Immunol       Date:  2009-01       Impact factor: 4.330

2.  Inhibition of murine hepatic tumor growth by liposomes containing a lipophilic muramyl dipeptide.

Authors:  P Brodt; J Blore; N C Phillips; J S Munzer; J D Rioux
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Elimination of group A streptococcal cell walls from mammalian tissues.

Authors:  J Gilbart; A Fox
Journal:  Infect Immun       Date:  1987-06       Impact factor: 3.441

4.  NOD2, the gene responsible for familial granulomatous uveitis, in a mouse model of uveitis.

Authors:  Holly L Rosenzweig; Tammy M Martin; Monica M Jann; Stephen R Planck; Michael P Davey; Koichi Kobayashi; Richard A Flavell; James T Rosenbaum
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-04       Impact factor: 4.799

5.  Enhancement of certain biological activities of muramyl dipeptide derivatives after conjugation to a multi-poly(DL-alanine)--poly(L-lysine) carrier.

Authors:  L Chedid; M Parant; F Parant; F Audibert; F Lefrancier; J Choay; M Sela
Journal:  Proc Natl Acad Sci U S A       Date:  1979-12       Impact factor: 11.205

6.  Arthritogenic activity of a synthetic immunoadjuvant, muramyl dipeptide.

Authors:  Z Zídek; K Maśek; Z Jiricka
Journal:  Infect Immun       Date:  1982-02       Impact factor: 3.441

7.  Anti-infectious activity of liposomal muramyl dipeptides in immunodeficient CBA/N mice.

Authors:  N C Phillips; L Chedid
Journal:  Infect Immun       Date:  1987-06       Impact factor: 3.441

8.  Modulation of adaptive immunity by different adjuvant-antigen combinations in mice lacking Nod2.

Authors:  Lilian O Moreira; Amber M Smith; Ashley A DeFreitas; Joseph E Qualls; Karim C El Kasmi; Peter J Murray
Journal:  Vaccine       Date:  2008-09-27       Impact factor: 3.641

9.  Screening for potential adjuvants administered by the pulmonary route for tuberculosis vaccines.

Authors:  Chenchen Wang; Pavan Muttil; Dongmei Lu; Adela Ayulia Beltran-Torres; Lucila Garcia-Contreras; Anthony J Hickey
Journal:  AAPS J       Date:  2009-03-10       Impact factor: 4.009

10.  Protective effect of muramyl dipeptide analogs against infections of Pseudomonas aeruginosa or Candida albicans in mice.

Authors:  E B Fraser-Smith; T R Matthews
Journal:  Infect Immun       Date:  1981-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.